Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
Adjuvant ICI therapy significantly improves the prognosis of patients with HCC at high risk of recurrence after curative resection. Six months of adjuvant ICI treatment may be insufficient.
Authors
- Li-Xin Pan (ORCID: https://orcid.org/0000-0002-3491-5095)
- Zhen-Ming Qin
- Peng Ye
- Jia-Song Chen
- Jia‐Yong Su (ORCID: https://orcid.org/0000-0002-0960-5394)
- Yaojie Li (ORCID: https://orcid.org/0009-0000-3544-5518)
- Jian‐Hong Zhong (ORCID: https://orcid.org/0000-0002-1494-6396)
- Da-Long Yang (ORCID: https://orcid.org/0000-0002-2931-1166)
- Xiaoling Xu (ORCID: https://orcid.org/0009-0002-8258-7935)
- Shaoping Liu
- Xiumei Liang
- Jinrong Liu (ORCID: https://orcid.org/0000-0003-3492-6445)
- Jianrong Li (ORCID: https://orcid.org/0000-0002-8232-9322)
- Fang Tang (ORCID: https://orcid.org/0000-0002-4378-594X)
- Baowei Zhao (ORCID: https://orcid.org/0000-0003-4224-6191)
- Qingli Luo (ORCID: https://orcid.org/0000-0001-6173-353X)
- Le Li (ORCID: https://orcid.org/0000-0003-3849-4854)
- Zhu‐Jian Deng
- Jun‐Jie Ou (ORCID: https://orcid.org/0009-0003-2700-1118)
- Yi-Li Ma
- Liang Ma
Institutions
- Guangxi Medical University (CN)
- Wuzhou University (CN)
- Guigang City People's Hospital (CN)
- Guangxi Center for Disease Prevention and Control (CN)
- Wuxi People's Hospital (CN)
Publication Details
- Journal
- Liver Cancer
- Published
- 2024-12-04
- DOI
- https://doi.org/10.1159/000542954
- Citations
- 10
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 2.83
Funders
- National Natural Science Foundation of China
- Guangxi Medical University
- Guangxi Key Research and Development Program
- Division of Graduate Education